Clinically meaningful phenotypes among SARS-CoV-2 reinfections: Informing prevention strategies for future pandemics

IF 4.3 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL
Lander Rodriguez-Idiazabal , Jose M. Quintana , Julia Garcia-Asensio , Maria Jose Legarreta , Nere Larrea , Irantzu Barrio
{"title":"Clinically meaningful phenotypes among SARS-CoV-2 reinfections: Informing prevention strategies for future pandemics","authors":"Lander Rodriguez-Idiazabal ,&nbsp;Jose M. Quintana ,&nbsp;Julia Garcia-Asensio ,&nbsp;Maria Jose Legarreta ,&nbsp;Nere Larrea ,&nbsp;Irantzu Barrio","doi":"10.1016/j.ypmed.2025.108259","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>Rapidly phenotyping patients can inform public health action plans in new pandemics. This study aimed to derive meaningful SARS-CoV-2 reinfected patients' phenotypes based on easily-available patient data and explore key epidemiological factors of reinfections.</div></div><div><h3>Methods</h3><div>We conducted a retrospective study of a cohort of SARS-CoV-2 reinfected adults from the Basque Country between January 1, 2021 and January 9, 2022. Phenotypes were defined in an unsupervised manner with clustering algorithms, incorporating variables like age, Charlson score, vaccination status and pre-existing treatments and comorbidities. Subsequently, clinical characteristics of phenotypes were compared, and their behavioral differences were evaluated through generalized additive models. Finally, their association with clinical outcomes was assessed.</div></div><div><h3>Results</h3><div>Four phenotypes were identified, which subsequently had a direct relationship with the risk levels for severe COVID-19 outcomes. The highest-risk group, phenotype 4, consisted of older adults −76 years, [62–85] (Median, [Interquartile range])- with multiple comorbidities and extensive baseline medication use. Phenotype 3 was slightly younger −64 years, [58–77]- but presented very low Charlson scores and few comorbidities, representing an intermediate-risk group. Phenotypes 1 and 2 were younger and healthier adults with similar clinical profiles. However, phenotype 1 showed a less protective attitude, with a higher rate of unvaccinated patients and shorter time intervals between infections.</div></div><div><h3>Conclusions</h3><div>We were able to classify reinfected patients into four distinct groups based on easily available variables, and these phenotypes had a direct relationship with COVID-19 clinical outcomes. Thus, rapidly phenotyping infected individuals can serve as a preventive public health strategy during new pandemics.</div></div>","PeriodicalId":20339,"journal":{"name":"Preventive medicine","volume":"193 ","pages":"Article 108259"},"PeriodicalIF":4.3000,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Preventive medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0091743525000428","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Objective

Rapidly phenotyping patients can inform public health action plans in new pandemics. This study aimed to derive meaningful SARS-CoV-2 reinfected patients' phenotypes based on easily-available patient data and explore key epidemiological factors of reinfections.

Methods

We conducted a retrospective study of a cohort of SARS-CoV-2 reinfected adults from the Basque Country between January 1, 2021 and January 9, 2022. Phenotypes were defined in an unsupervised manner with clustering algorithms, incorporating variables like age, Charlson score, vaccination status and pre-existing treatments and comorbidities. Subsequently, clinical characteristics of phenotypes were compared, and their behavioral differences were evaluated through generalized additive models. Finally, their association with clinical outcomes was assessed.

Results

Four phenotypes were identified, which subsequently had a direct relationship with the risk levels for severe COVID-19 outcomes. The highest-risk group, phenotype 4, consisted of older adults −76 years, [62–85] (Median, [Interquartile range])- with multiple comorbidities and extensive baseline medication use. Phenotype 3 was slightly younger −64 years, [58–77]- but presented very low Charlson scores and few comorbidities, representing an intermediate-risk group. Phenotypes 1 and 2 were younger and healthier adults with similar clinical profiles. However, phenotype 1 showed a less protective attitude, with a higher rate of unvaccinated patients and shorter time intervals between infections.

Conclusions

We were able to classify reinfected patients into four distinct groups based on easily available variables, and these phenotypes had a direct relationship with COVID-19 clinical outcomes. Thus, rapidly phenotyping infected individuals can serve as a preventive public health strategy during new pandemics.
SARS-CoV-2再感染的临床意义表型:为未来大流行的预防策略提供信息
目的:快速分型患者可以为新流行的公共卫生行动计划提供信息。本研究旨在基于可获得的患者资料,获得有意义的SARS-CoV-2再感染患者的表型,并探索再感染的关键流行病学因素。方法:我们对巴斯克地区2021年1月1日至2022年1月9日期间SARS-CoV-2再感染成人队列进行了回顾性研究。表型是用聚类算法以无监督的方式定义的,包括年龄、查理森评分、疫苗接种状况、既往治疗和合并症等变量。随后,比较表型的临床特征,并通过广义加性模型评估其行为差异。最后,评估它们与临床结果的关系。结果:确定了四种表型,这些表型随后与严重COVID-19结局的风险水平有直接关系。最高风险组,表型4,包括老年人-76 岁,[62-85](中位数,[四分位数范围])-有多种合并症和广泛的基线药物使用。表型3稍年轻,为64 岁[58-77],但Charlson评分非常低,合并症很少,属于中危组。表型1和2是具有相似临床特征的更年轻、更健康的成年人。然而,表现型1表现出较少的保护态度,未接种疫苗的患者比例较高,感染间隔时间较短。结论:我们能够根据容易获得的变量将再感染患者分为四组,这些表型与COVID-19临床结果有直接关系。因此,在新的大流行期间,快速分型受感染个体可作为一种预防性公共卫生策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Preventive medicine
Preventive medicine 医学-公共卫生、环境卫生与职业卫生
CiteScore
7.70
自引率
3.90%
发文量
0
审稿时长
42 days
期刊介绍: Founded in 1972 by Ernst Wynder, Preventive Medicine is an international scholarly journal that provides prompt publication of original articles on the science and practice of disease prevention, health promotion, and public health policymaking. Preventive Medicine aims to reward innovation. It will favor insightful observational studies, thoughtful explorations of health data, unsuspected new angles for existing hypotheses, robust randomized controlled trials, and impartial systematic reviews. Preventive Medicine''s ultimate goal is to publish research that will have an impact on the work of practitioners of disease prevention and health promotion, as well as of related disciplines.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信